Safety of HRX215 in Patients After Minor and Major Liver Resection

Safety of HRX215 in Patients After Minor and Major Liver Resection is a phase 1/2, randomised interventional study registered as NCT06638502 by HepaRegeniX GmbH, with a registry enrolment figure of 80 participants, started 2025-05-06 and due to reach its primary completion in 2027-07-31. Interventions recorded: HRX215 capsules; Placebo capsules. Conditions listed: Liver Resection; Colorectal Carcinoma Liver Metastases. Primary outcome: Adverse Events (AEs) observed; HRX215 plasma levels. Colorectal eligibility wording from the registry: "* Participants with liver metastases originating from colon carcinoma planned for R0-intended hepatectomy for colorectal liver metastases". Sites: France, Germany, Israel, Spain, United States. No results are recorded here; the registry entry is the source.